Navigation Links
New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Date:10/16/2007

NUTLEY, N.J., Oct. 17 /PRNewswire/ -- Ten abstracts providing new analyses of data from six major Phase III renal anemia studies for MIRCERA(R) will be presented at the upcoming 40th Annual Meeting of the American Society of Nephrology (ASN) in San Francisco on November 2 - 5, 2007.

Among the highlights will be new analyses from maintenance studies, including MAXIMA, PROTOS, STRIATA and RUBRA, and correction studies, including ARCTOS and AMICUS.

Please note all information presented at the ASN annual meeting is embargoed for media release until one hour after the time of presentation.

Abstracts accepted for the ASN annual meeting include:

-- Once-monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb)

in dialysis patients (pts), irrespective of age or gender. S. Fishbane

et al. (SU-PO779. November 4: 10:00 a.m. - 12:00 p.m. PST. Exhibit

Hall, Moscone Center)

-- Stable hemoglobin (Hb) levels are maintained with once-monthly C.E.R.A.

in dialysis patients (pts), irrespective of mode of vascular access. F.

Locatelli et al. (SU-PO822. November 4: 10:00 a.m. - 12:00 p.m. PST.

Exhibit Hall, Moscone Center)

-- Once-monthly C.E.R.A. maintains stable hemoglobin (Hb) in patients

(pts) with chronic kidney disease (CKD), irrespective of baseline iron

levels. A. Nissenson et al. (SU-PO819. November 4: 10:00 a.m. - 12:00

p.m. PST. Exhibit Hall, Moscone Center)

-- C.E.R.A. maintains stable hemoglobin (Hb) in chronic kidney disease

(CKD), regardless of albumin or dialysis adequacy (Kt/V). W. Sulowicz

et al. (Publication Only)

-- Effect of baseline hemoglobin (Hb) on Hb stability in patients (pts)

with chronic kidney disease (CKD) receiving once-monthly C.E.R.A. N.W.

Levin et al. (SU-PO817. November 4: 10:00 a.m. - 12:00 p.m. PST.

Exhibit Hall, Moscone Center)

-- Anemia correction wi
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
8. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
9. AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to Be Featured at AACR
10. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
11. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 STAAR Surgical ... manufacturer and marketer of implantable lenses and delivery systems ... quarter ended July 4, 2014 of $20.0 million, a ... quarter of 2013. On a constant currency basis, revenues ... to the second quarter of 2013.  The effect of ...
(Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... June 30, 2014. Financial Results for the Six ... revenue for the quarter ended June 30, 2014 increased to ... 30, 2013 primarily due to IMBRUVICA ® (ibrutinib) net ... for the six months ended June 30, 2014 increased to ...
(Date:7/31/2014)... 2014  UBM Medica US announces that ... oncologists, presents exclusive slide shows dealing with communication in ... cancer care. Cancer Network, the ... news, blogs, and podcasts about the latest clinical findings. ... , End-of-life care is challenging for even ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6
... SANTA BARBARA, Calif., Dec. 6, 2010 Direct ... has donated critically needed medical supplies to assist cholera ... University Hospital (JUH) in Cap-Haitien. JUH is the main public ... I.V. solutions and supplies will also be distributed to the ...
... DIEGO, Dec. 6, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, ... of their first-in-class CK2 inhibitor at the 52nd Annual Meeting ... on December 4-7 in Orlando, FL, the company announced today. ... on targeting CK2, a protein kinase that is essential for ...
Cached Medicine Technology:CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti 2CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti 3Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 2Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 3
(Date:8/1/2014)... August 01, 2014 Stryker hip ... of the 2012 Rejuvenate and ABG II Modular-Neck ... New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... proceeding, the Court has issued a Final ... and all hard copy and electronic materials produced ...
(Date:8/1/2014)... Almost 140 people die every year in accidents ... But there are several simple ways to ... coordinator at Cincinnati Children,s Hospital Medical Center,s Comprehensive ... news release. "As families begin to prepare ... parents and children to go over school bus ...
(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly experienced ... of power morcellators in gynecological surgeries, Bernstein Liebhard LLP ... to withdraw a number of power morcellators marketed by ... a report from The New York Times, some critics ...
(Date:8/1/2014)... Las Vegas, NV (PRWEB) August 01, 2014 ... issues and opportunities for independent community pharmacies. At ... tradeshow, pharmacists are equipped with practices and resources ... General Session, AmerisourceBergen leaders focused on critical issues ... to learn, optimize and grow. , ThoughtSpot ...
(Date:8/1/2014)... NY, August 1, 2014Lesbian, gay, bisexual, and transgender individuals ... same problems as some of their heterosexual and cisgendered ... often face additional physiological and legal challenges to ... advances in assisted reproduction options is presented in the ... Possibilities ," published in LGBT Health ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Expert Offers School Bus Safety Tips 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2
... 9, 2010) An ultra-low-molecular-weight heparin called semuloparin ... venous thromboembolism in orthopedic surgery patients in a ... committee chaired by McMaster University professor Dr. Alexander ... completed international clinical studies on short-term venous thromboembolism ...
... ... ... bliss is not all it’s cracked up to be. Oh, sure, it’s great while it ... of July sparkler. , , ,Long-lasting, transformational marriages rely on more than passion to thrive, ...
... ... Khoi Nguyen and Dennis McDowell have joined their executive sales staff in the Houston ... the area,s most influential hospitals and providers. Accel is the Company’s top tier network ... providers. , ...
... BUENOS AIRES, ARGENTINA, July 9 Pfizer Inc, the ... of a number of hemophilia studies will be presented ... taking place July 10-14, 2010, in Buenos Aires, Argentina. ... Xa as a potential new approach to restoring hemostasis, ...
... ... nation to receive the “Best Practice” award from Safety Net Solutions. The award recognizes the ... for the communities they serve. , ... (Vocus) July 8, 2010 -- St. Elizabeth’s Dental Clinic is one ...
... ... health problems, Sam’s Club is hosting free health screenings in more than 400 of its ... ... To help its members and community residents detect a range of preventable health problems, Sam’s ...
Cached Medicine News:Health News:Drug study shows improvement in major orthopedic surgery care 2Health News:When the Fireworks Fizzle: How to Stoke the Flames of Lasting Love 2Health News:HealthSmart Adds Experienced Professionals to Houston Sales Force 2Health News:Pfizer Hemophilia presents new data at the World Federation of Hemophilia 2010 Congress 2Health News:St. Elizabeth Dental Clinic Named one of the Best in the Nation 2Health News:Sam's Club Hosts Health Screenings July 10 2
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
... are liquid controls designed to ... procedures that detect Chlamydia trachomatis ... are specimen specific, they can ... or endocervical/urethral swabs throughout the ...
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: